Form 8-K - Current report:
SEC Accession No. 0001140361-25-026946
Filing Date
2025-07-23
Accepted
2025-07-23 16:29:39
Documents
12
Period of Report
2025-07-23
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K ef20052517_8k.htm   iXBRL 8-K 25941
  Complete submission text file 0001140361-25-026946.txt   153119

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rckt-20250723.xsd EX-101.SCH 3877
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20250723_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20250723_pre.xml EX-101.PRE 16052
14 EXTRACTED XBRL INSTANCE DOCUMENT ef20052517_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 251143414
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)